Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2009
12/02/2009CN101590015A Cationic adhesion type mycophenolate mofetil nano eye drop
12/02/2009CN101590010A Mycophenolate mofetil intraocular medicament releasing system
12/02/2009CN101590009A Novel preparation of tilmicosin and salt of same for livestock and preparation method thereof
12/02/2009CN100563718C Gas-filled microvesicle assembly for contrast imaging
12/02/2009CN100563716C Bio-compatible monodisperse nano polymer carrier and its preparation and medicine-carrying method
12/02/2009CN100563715C Taxdol self-assembled precursor liposome and its preparation method
12/02/2009CN100563714C Naloxone hydrochloride nano granule powder injection formulation and preparation thereof
12/02/2009CN100563713C External preparation for skin
12/02/2009CN100563712C Liquid formulations of tumor necrosis factor-binding proteins
12/02/2009CN100563711C Slow-released anticancer injection
12/02/2009CN100563710C Slow-released anticancer medicine preparation containing pyrimidine analog
12/02/2009CN100563665C Cow sex-control sperm freezing preservation seminal fluid dilution
12/02/2009CN100563664C Liquid medicine preparation and its preparing process and use
12/02/2009CN100563658C Solid dispersoid or medicinal solid dispersoid preparation of phenylalanine derivative
12/02/2009CN100563656C Tamper-resistant oral opioid agonist
12/02/2009CN100563655C Compositions for treating infection in cattle and swine and its uses
12/02/2009CN100563649C Chuanhuning lipid freeze-dry powder agent and preparing method thereof
12/02/2009CN100563648C Composition for oral administration containing alkylene dioxybenzene derivative
12/02/2009CN100563646C Oxaliplatinum liposome glucose formulation preparation method
12/02/2009CN100563645C Beisalutin sustained-release implantation agent for curing entity tumour
12/02/2009CN100563644C Carmustine sustained-release implantation agent for curing entity tumour
12/02/2009CN100563642C Chloromycetin eyedrops and preparation method thereof
12/02/2009CN100563640C Method for preparing micro-spheres using modified ploylactic acid material as shell material
12/02/2009CN100563638C Nifedipine controlled-releasing tablet and preparation method thereof
12/02/2009CN100563637C A medicine core composition of controlled release drug delivery and controlled release preparation as well as its preparing method
12/02/2009CN100563633C Hydrochloric acid diltiazem freeze-dried powder injection for injections and preparation method thereof
12/02/2009CN100563632C Fleraxacin for injection and preparation method thereof
12/02/2009CN100563629C Compound turmeric acne-eliminating gel and its preparation
12/02/2009CN100563628C Bendalysine eye gel preparation and its making method
12/01/2009US7625961 A fermentation solid from a grain, root, or tuber extruded and compounded with a thermoplastic resin, a thermosetting resin, or adhesive polymer, and can also be foamed
12/01/2009US7625928 Prevent, therapy of side effect of radiotherapy; applying to skins, mucous membranes
12/01/2009US7625878 Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
12/01/2009US7625866 Increased content of high molecular weight multimers; hemophilia and blood disorder treatment
12/01/2009US7625862 Method for making a high oxygen affinity modified hemoglobin for oxygen transport
12/01/2009US7625588 Continuous process for production of oil seed protein isolate
12/01/2009US7625584 Isolating and stabilizing antihemophila factor for use in dosage cancentration for treatment of hemophlia
12/01/2009US7625582 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
12/01/2009US7625579 A substrate having a vapor deposited furanone compounds, covalent bonding through etherification or amination; protective coatings on medical equipment, seeds, fibrics, wool, hair, silk, cotton, chitin, collagen, animal
12/01/2009US7625574 Moisturizers; transdermal absorption; ethylene oxide-propylene oxide adduct
12/01/2009US7625562 Generation of cartilage using magnetizable particles
12/01/2009US7625548 Methods and apparatus for producing nanoscale particles
12/01/2009CA2572461C Physiological compatible film
12/01/2009CA2442311C Amorphous cefditoren pivoxil composition and process for producing the same
12/01/2009CA2407210C Liposome drug delivery
12/01/2009CA2399426C Endoparasiticidal gel composition
12/01/2009CA2376593C Method of particle formation
12/01/2009CA2315237C Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
12/01/2009CA2107513C Fusion protein for prodrug activation
11/2009
11/26/2009WO2009143367A2 Egf-a domain-mediated modulation of pcsk9
11/26/2009WO2009143345A2 Nucleic acid silencing agent-protein conjugates and use thereof for treating hcv-related disorders
11/26/2009WO2009143175A2 Sensory-specific local anesthesia and prolonged duration local anesthesia
11/26/2009WO2009142950A1 Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
11/26/2009WO2009142893A2 Methods and compositions for the delivery of bioactive compounds
11/26/2009WO2009142852A2 Process for manufacturing flowable powder drug compositions
11/26/2009WO2009142754A1 Dendritic conjugates and methods of use
11/26/2009WO2009142328A1 Camptothecin polymer derivative and uses of the same
11/26/2009WO2009142326A1 Docetaxel polymer derivative, method for producing same and use of same
11/26/2009WO2009142307A1 Peptide capable of extending half-life of peptide of interest in plasma
11/26/2009WO2009142255A1 Cellulose powder having excellent segregation preventive effect, and compositions thereof
11/26/2009WO2009141687A1 New optically pure compounds for improved therapeutic efficiency
11/26/2009WO2009141433A1 Low viscosity compositions comprising a pegylated gla-domain containing protein
11/26/2009WO2009141418A1 Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
11/26/2009WO2009141239A1 A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
11/26/2009WO2009141170A2 Compounds suited as nanocarriers for active agents and their use
11/26/2009WO2009141142A1 Nanoparticles functionalized with sulfated amino alcohols for the inhibition of selectin-mediated cell adhesion
11/26/2009WO2009141050A2 Linear self-eliminating oligomers
11/26/2009WO2009140763A1 Novel ghrelin analogues
11/26/2009WO2009140755A1 An anti-cancer cytotoxic monoclonal antibody
11/26/2009WO2009140754A1 An anti-cancer cytotoxic monoclonal antibody
11/26/2009WO2009114520A3 Compositions for treatment with metallopeptidases, methods of making and using the same
11/26/2009WO2009112740A3 Large particle size crystallised maltitol powder, method for preparing same and applications thereof, particularly in chocolate production
11/26/2009WO2009108868A3 Radiolabeled hedgehog derivatives for imaging and therapy
11/26/2009WO2009087663A3 Oral controlled release coated tablet
11/26/2009WO2009080699A3 Peg-interferon-beta formulations
11/26/2009WO2009079679A3 Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
11/26/2009WO2009073533A3 Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
11/26/2009WO2009071850A3 Nanoparticles of therapeutic agents having low water solubility
11/26/2009WO2009058585A3 Non-aqueous water-miscible materials as vehicles for drug delivery
11/26/2009WO2009058387A3 Oligomer-nitroimidazole anti-infective conjugates
11/26/2009WO2009042922A3 Peptide-peptidase inhibitor conjugates and methods of making and using same
11/26/2009WO2009026430A3 Liposome formulations of boronic acid compounds
11/26/2009WO2008094675A3 Novel biomaterials and methods for making and using same
11/26/2009US20090292112 provide polypeptides inter alia that have been identified as novel proteins with homology to the Mindin family of extracellular matrix proteins (RG1); prostate cancer or benign prostatic hyperplasia, which is alleviated by decreasing the level of RG1 activity
11/26/2009US20090292029 Bioabsorbable polymers from bioabsorbable polyisocyanates and uses thereof
11/26/2009US20090292016 Stable Pharmaceutical Compositions Containing Pravastatin
11/26/2009US20090292013 In-Situ Forming Implant for Animals
11/26/2009US20090292005 L- alpha -dioleoyl phosphatidyl{14-N-(1-deoxylactito-1-yl)amino-3,6,9,12-tetraoxa}tetra decanol; 2-O-{2-N-(1-deoxylactito-1-yl)aminoethyl} carbamoyl-1,3-O-dioleoyl glycerol; galactose, a suitable spacer and a certain lipid, a drug carrier; efficiently transferred into the liver
11/26/2009US20090291930 Fibrous calcium pyrophosphate particles and methods of making and using same
11/26/2009US20090291925 Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions
11/26/2009US20090291911 Rehydratable polysaccharide particles and sponge
11/26/2009US20090291886 Transmucosal delivery of peptides and proteins
11/26/2009US20090291457 Re-targeted toxin conjugates
11/26/2009US20090291146 Process for manufacturing lactose
11/26/2009US20090291135 Direct compression polymer tablet core
11/26/2009US20090291120 Hydrophilic Polyurethane Compositions
11/26/2009US20090291106 Biodegradable block copolymers with modifiable surface
11/26/2009US20090291105 Instant Vesicular Product
11/26/2009US20090291103 Quality control methods for oil-in-water emulsions containing squalene
11/26/2009US20090291098 Immunogenic LHRH compositions and methods relating thereto
11/26/2009US20090291093 Immunoconjugates with an Intracellularly-Cleavable Linkage
1 ... 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 ... 1712